Skip to content
Biodatica
Start free

Grupo Espanol de Tumores Neuroendocrinos

Badalona, Barcelona

OncologyPhase II
Sign in to watch

What changed

Phase II trial registered: Platinum-doublet Chemotherapy and Nivolumab for the Treatment of Subjects With Neuroendocrine Neoplasms (NENs) of the Gastroenteropancreatic (GEP) Tract or of Unknown (UK) Origin.

Jan 2025Trial registeredJan 13, 2025Source filing (opens the source filing in a new tab)

Momentum

31no change

Momentum 31 out of 100, unchanged since the last recompute.

Little recent filing activity, or the events on file have decayed.

Runway (estimate)

—unknown

No disclosed raise on file, so there is nothing to model from.

Stage

Phase II

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

  1. Trial

    PHASE2 registered

    Oct 11, 2019

    Neuroendocrine Tumors, Neuroendocrine Neoplasm, Gastroenteropancreatic Neuroendocrine Tumor · COMPLETED · sponsor: Grupo Espanol de Tumores Neuroendocrinos · Platinum-doublet Chemotherapy and Nivolumab for the Treatment of Subjects With Neuroendocrine Neoplasms (NENs) of the Gastroenteropancreatic (GEP) Tract or of Unknown (UK) Origin.

    ClinicalTrials.gov · NCT03980925 (opens the source filing in a new tab)

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources